ATE235893T1 - Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung - Google Patents

Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung

Info

Publication number
ATE235893T1
ATE235893T1 AT96914626T AT96914626T ATE235893T1 AT E235893 T1 ATE235893 T1 AT E235893T1 AT 96914626 T AT96914626 T AT 96914626T AT 96914626 T AT96914626 T AT 96914626T AT E235893 T1 ATE235893 T1 AT E235893T1
Authority
AT
Austria
Prior art keywords
active ingredient
biologically active
preparation containing
oral preparation
zonula occludens
Prior art date
Application number
AT96914626T
Other languages
English (en)
Inventor
Alessio Fasano
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/443,864 external-priority patent/US5827534A/en
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE235893T1 publication Critical patent/ATE235893T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT96914626T 1995-05-24 1996-05-16 Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung ATE235893T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/443,864 US5827534A (en) 1995-05-24 1995-05-24 Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US08/598,852 US5665389A (en) 1995-05-24 1996-02-09 Oral dosage composition for intestinal delivery and method of treating diabetes
PCT/US1996/006870 WO1996037196A1 (en) 1995-05-24 1996-05-16 Oral dosage composition for intestinal delivery and method of use of the same

Publications (1)

Publication Number Publication Date
ATE235893T1 true ATE235893T1 (de) 2003-04-15

Family

ID=27033689

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96914626T ATE235893T1 (de) 1995-05-24 1996-05-16 Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung

Country Status (9)

Country Link
US (1) US5665389A (de)
EP (1) EP0828481B1 (de)
JP (2) JP3846901B2 (de)
AT (1) ATE235893T1 (de)
AU (1) AU702385B2 (de)
CA (1) CA2222018A1 (de)
DE (1) DE69627147T2 (de)
ES (1) ES2194989T3 (de)
WO (1) WO1996037196A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US5912323A (en) * 1997-02-20 1999-06-15 University Of Maryland, Baltimore Zonula occludens toxin receptors
US5864014A (en) * 1997-02-20 1999-01-26 University Of Maryland At Baltimore Zonula occludens toxin receptor
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
AU754142B2 (en) * 1998-09-14 2002-11-07 University Of Maryland At Baltimore Method of using zot or zonulin to inhibit lymphocyte proliferation in an antigen-specific manner
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
AU2001249067A1 (en) * 2000-05-19 2001-12-03 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
BR0317879A (pt) 2003-01-10 2005-12-06 Ct Investig Y Estudios Del Ipn Usos da proteìna vp4 de rotavìrus e de anticorpos monoclonais ou policlonais, composição farmacêutica, agente terapêutico, medicamentos, métodos para tratar diabete e câncer, para reduzir a adesão celular não desejada que pode ocorrer entre células de tumor ou células normais e para determinar as regiões ou os peptìdios derivados de proteìnas vp4, vp8, e, peptìdeo
EP1605895A4 (de) * 2003-03-06 2011-08-24 Emisphere Tech Inc Orale insulintherapien und protokoll
US7286223B2 (en) * 2003-03-18 2007-10-23 Loma Linda University Medical Center Method and apparatus for detecting embedded rebar within an interaction region of a structure irradiated with laser light
EP1648917A4 (de) * 2003-07-15 2008-11-12 Univ Maryland Agonistpolypeptid des rezeptors für zot und zonulin
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
BRPI0513673B8 (pt) * 2004-08-03 2021-07-27 Vital Health Sciences Pty Ltd método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
TW200637573A (en) * 2005-01-14 2006-11-01 Univ Maryland Peptide for delivery of mucosal vaccines
AR057058A1 (es) * 2005-06-09 2007-11-14 Alba Therapeutics Corp Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
ES2459018T3 (es) * 2006-02-09 2014-05-07 Alba Therapeutics Corporation Formulaciones de efectores de la unión estrecha
US8728491B2 (en) * 2007-05-07 2014-05-20 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
EP2725035A1 (de) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antikörpertherapie zur Verwendung im Verdauungstrakt
EP2062909A1 (de) 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Herstellung von Peptiden und Reinigungsverfahren
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
EP2531047B1 (de) 2010-02-05 2024-11-13 Phosphagenics Limited Träger mit einem nichtneutralisierten tocopherylphosphat
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
RU2639483C2 (ru) 2012-03-19 2017-12-21 Сидара Терапьютикс, Инк. Режимы дозирования для соединений класса эхинокандинов
CN103923216B (zh) * 2014-04-22 2016-04-27 吉林大学 多功能模块融合蛋白及其在提高蛋白质类药物口服生物利用度中的应用
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
CA3052975A1 (en) 2017-02-10 2018-08-16 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating disease associated with permeability of intestinal epithelium

Also Published As

Publication number Publication date
AU702385B2 (en) 1999-02-18
DE69627147D1 (de) 2003-05-08
DE69627147T2 (de) 2003-12-11
JP3846901B2 (ja) 2006-11-15
EP0828481A4 (de) 1999-06-09
AU5792996A (en) 1996-12-11
ES2194989T3 (es) 2003-12-01
JP2003155253A (ja) 2003-05-27
EP0828481B1 (de) 2003-04-02
CA2222018A1 (en) 1996-11-28
JPH11505844A (ja) 1999-05-25
WO1996037196A1 (en) 1996-11-28
US5665389A (en) 1997-09-09
EP0828481A1 (de) 1998-03-18

Similar Documents

Publication Publication Date Title
ATE235893T1 (de) Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
EP1028715A4 (de) Dosiszusammensetzung zur nasalen verabreichung und verfahren zu deren verwendung
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
SE9504661D0 (sv) New compounds
NO961136L (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
GEP20053602B (en) Aripiprazole for Oral Administration
NO20083842L (no) Anvendelse av opploselig lymfotoksin-beta-reseptor for fremstilling av medikamenter
NO954996L (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
FI113644B (fi) Menetelmä terapeuttisesti aktiivisten N-substituoitujen 3- atsabisykloalkaanijohdannaisten valmistamiseksi
MX9709146A (es) Compuestos novedosos, preparacion y uso de los mismos.
DE69630145D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE311227T1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
NO996108L (no) 9-oksinerytromycinderivater
DE60019334D1 (de) Antivirale arznei
TR200001147T2 (tr) Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı
TR199900770T2 (xx) Nazal poliplerin tedavisinde bir H+, K+-ATPase'�n kullan�lmas�.
ATE193533T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
FI945780A7 (fi) Uudet biologisesti aktiiviset eburnameniinijohdannaiset, niitä sisältävät farmaseuttiset koostumukset ja menetelmä niiden valmistamiseksi
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
AU3777197A (en) Cyclosporin formulation
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
ATE215941T1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties